Clinical trials: Cardiovascular Risk Profile
Metabolic Syndrome X
Exercise and Technology to Reduce Risk in a Rural Population With Metabolic Syndrome
Cardiovascular diseases are the leading cause of death among Canadians. In those with diabetes, cardiovascular complications are responsible for more than 70% of deaths.
- Trial name
- NCT01944124
- Testing
- Mobile Health, Exercise Prescription
- Where
- Canada
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Cardiovascular Disease Risk Factor, Insulin Resistance
Acute Postprandial Effects of Functional Ice Cream With Cimarrón Bean Extrudate in Adults
The goal of this non-randomized clinical trial is to evaluate the acute postprandial metabolic effects of a functional ice cream enriched with Cimarrón bean (Phaseolus vulgaris L.
- Conditions
- Cardiovascular Disease Risk Factor, Insulin Resistance, Overweight (BMI > 25), Hyperglycaemia
- Trial name
- ICE-CBE-GLULIP (NCT07053267)
- Testing
- Funrional Ice Cream
- Where
- Chile
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Talca
Insulin Resistance, Oxidative Stress
Microencapsulated Fish Oil or Conjugated Linoleic Acid in Metabolic Syndrome
Our aim was to assess the effects of a hypocaloric diet, including diet fruit jelly with microencapsulated fish oil or conjugated linoleic acid or placebo, on anthropometry, body composition, insulin resistance and lipid profile…
- Conditions
- Insulin Resistance, Oxidative Stress, Lipid Profile, Blood Pressure
- Trial name
- NCT02183922
- Testing
- microencapsulated conjugated linoleic acid, microencapsulated fish oil, light fruit jam
- Where
- Brazil
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do Rio de Janeiro
Schizophrenia Disorder, Metabolic Syndrome
Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome
Patients with schizophrenia on second-generation antipsychotics have a high burden of metabolic syndrome and elevated cardiovascular risk, with few effective treatment options.
- Conditions
- Schizophrenia Disorder, Metabolic Syndrome, Antipsychotic-induced Weight Gain, Cardiovascular Risk
- Trial name
- NCT07770282
- Testing
- Semaglutide + TAU
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar